Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Blood (2022) 140 (Supplement 1): 9443–9445.

https://doi.org/10.1182/blood-2022-158245

Published: 2022

Journal Articles

Subcutaneous Epcoritamab in Combination with R 2 (Rituximab and Lenalidomide) in Patients with Relapsed or Refractory Follicular Lymphoma: Preliminary Results from a Phase 1/2 Trial

Kim M Linton, Björn Wahlin, Sirpa Leepä, Franck Morschhauser, Brian Elliot, Tracy Liu, Mariana Cota Stirner, Aqeel Abbas, Lorenzo Falchi

Blood (2021) 138 (Supplement 1): 3535.

https://doi.org/10.1182/blood-2021-146629

Published: 2021

Journal Articles

Subcutaneous Epcoritamab in Combination with R-CHOP in Patients with Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma: Preliminary Results from a Phase 1/2 Trial

David Belada, Jacob Haaber Christensen, Kristina Drott, Sylvia Snauwaert, Joshua Brody, Mayur Narkhede, Fritz Offner, Brian Elliot, Tracy Liu, Mariana Cota Stirner, Aqeel Abbas, Lorenzo Falchi, Michael Roost Clausen

Blood (2021) 138 (Supplement 1): 1413.

https://doi.org/10.1182/blood-2021-146569

Published: 2021

Journal Articles

Association of Baseline and Postinfusion Biomarkers with Safety and Efficacy Endpoints in Patients Treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the Phase 1/2 Evolve Study (NCT03430011)

Julia Piasecki, BA, Todd Devries, PhD, Aditya Radhakrishnan, PhD, Yan Li, PhD, Mark Heipel, BS, Brian A. Fox, PhD, Valeria Beckett, MS, Mariana Cota Stirner, MD PhD, Kristin Conte, MPH, Thomas Doerr, MSc, Sham Mailankody, MBBS, Sandy W. Wong, MD, Philip L. McCarthy, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-137786

Published: 2020